Why Innate Pharma S.A.’s (IPHA) Stock Is Up 7.14%
As of Wednesday, November 04, Innate Pharma S.A.’s IPHA share price has surged by 7.14%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Commentary & Analysis
Why Innate Pharma S.A.’s (IPHA) Stock Is Down 7.01%
As of Thursday, October 22, Innate Pharma S.A.’s IPHA share price has dipped by 7.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Innate Pharma S.A.’s (IPHA) Stock Is Up 5.75%
As of Tuesday, October 20, Innate Pharma S.A.’s IPHA share price has surged by 5.75%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Innate Pharma S.A.’s (IPHA) Stock Is Down 8.64%
As of Monday, October 12, Innate Pharma S.A.’s IPHA share price has dipped by 8.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Innate Pharma S.A.’s (IPHA) Stock Is Up 8.37%
As of Friday, October 09, Innate Pharma S.A.’s IPHA share price has surged by 8.37%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $131.8 | $219.9 | 25% |
|
| Shares Out (Mil) | 107.2 | 54.1 | 63% |
|
| Institutional Ownership | 89.1% | 92.9% | 57% |
|
| Float (Mil) | 68.9 | 41.4 | 53% |
|
| Beta | 0.88 | 0.95 | 53% |
|
| Avg Daily Volume (000s) | 20 | 522 | 22% |
|
| Price Change (52-week) |
(21.7%) | 44.7% | 34% |
|
| Growth | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (34.1%) | 13.2% | 1% |
|
| Net Income (5yr) | 5.9% | (10.1%) | 49% |
|
| EPS (5yr) | 8.2% | 15.8% | 44 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 12.5% | (15.7%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $38 | 9% |
|
| Net Income (TTM) (Mil) | ($54) | ($44) | 15% |
|
| EPS (TTM) | ($0.583) | ($1.500) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($49) | ($35) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($55) | $0 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $152 | $166 | 24% |
|
| Valuation | IPHA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.06 | na |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IPHA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (307.6%) | 67.3% | 1% |
|
| Net Margin | (483.8%) | (61.0%) | 2% |
|
| ROA | (72.9%) | (47.5%) | 8% |
|
| ROE | 269.5% | (52.7%) | 99% |
|
| Liabilities to Assets | 216.7% | 29.6% | 99% |
|
| F-Score | 3 | 3 | 18% |
|
Innate Pharma S.A. did not pass any screens on 11/6/2026.
